Agilent Technologies Inc. (A)

This month's preferred stock IPO market is frozen, dominated by “Par Cross” and “Insider Buying” alerts, reflecting investor uncertainty due to trade tensions. The trade war and tariffs have created s...

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

City Office REIT's Series A Preferred Shares offer a tempting yield despite recent accounting losses and systemic pressures, suggesting a potential buying opportunity. The shares are cumulative, redee...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 i...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the use as a Compan...

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Citi analyst Patrick Donnelly added a "90-day positive catalyst watch" on shares of Agilent while keeping a Buy rating on the name with a $165 price target. At a time when investor sentiment on tools ...

Fear at extremes: Investor and consumer sentiment is near historic lows, signaling a high-probability buying opportunity, historically followed by strong 12-month gains. Economic reality check: Real-t...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics' FDA approval for AUCATZYL®, a recently approved CAR T ther...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE N...